N. N. Salama

发表

The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents.

N. Eddington, N. N. Salama, K. Scott, 2004, International journal of pharmaceutics.

MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells.

R. Ho, T. Bui, N. N. Salama, 2006, Journal of pharmaceutical sciences.

Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis

B. Mueller, Katie E Cardone, D. Grabe, 2012, Antimicrobial Agents and Chemotherapy.

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma

S. Achilefu, D. Hallahan, R. Vij, 2020, Nature Communications.

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma

R. Vij, A. Azab, Zhe Wang, 2020, Cancers.

INJECTABLE HYDROGELS FOR LOCALIZED CHEMO- AND RADIO-THERAPY IN BRAIN TUMORS

S. Goddu, C. Tsien, N. Fettig, 2018 .

The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice.

R. Ho, E. Kelly, T. Bui, 2005, Journal of pharmaceutical sciences.

Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis

Rachel F. Eyler, Michael Heung, Jonathan H. Segal, 2019, Renal failure.

Targeting E-selectin to Tackle Cancer Using Uproleselan

A. Azab, N. N. Salama, B. Muz, 2021, Cancers.

Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy

N. N. Salama, M. Churchwell, B. A. Mueller, 2011, Blood Purification.

Etanercept Clearance during an in vitro Model of Continuous Venovenous Hemofiltration

K. Cooke, N. N. Salama, Geoffrey M. Fleming, 2009, Blood Purification.

Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis

Michael Heung, K. Sowinski, N. N. Salama, 2011, Critical care medicine.

Enaminones: Exploring additional therapeutic activities.

S. Kombian, N. Eddington, N. N. Salama, 2007, Journal of pharmaceutical sciences.

Synthesis and anticonvulsant activity of enaminones. Part 7. Synthesis and anticonvulsant evaluation of ethyl 4-[(substituted phenyl)amino]-6-methyl-2-oxocyclohex-3-ene-1-carboxylates and their corresponding 5-methylcyclohex-2-enone derivatives.

K R Scott, James P Stables, J. Stables, 2003, European journal of medicinal chemistry.

DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents

N. Eddington, N. N. Salama, K. Scott, 2004, Biopharmaceutics & drug disposition.

Multidrug resistance and anticonvulsants: new studies with some enaminones.

N. Eddington, N. N. Salama, K. Scott, 2004, Current medicinal chemistry.

Preclinical evaluation of the pharmacokinetics, brain uptake and metabolism of E121, an antiepileptic enaminone ester, in rats

K. Bauer, N. Eddington, N. N. Salama, 2003, Biopharmaceutics & drug disposition.

Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.

Michael Heung, Jonathan H. Segal, N. N. Salama, 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis.

Michael Heung, Jonathan H. Segal, N. N. Salama, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Tight junction modulation and its relationship to drug delivery.

Alessio Fasano, A. Fasano, Natalie D Eddington, 2006, Advanced drug delivery reviews.

Effect of the biologically active fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral absorption of mannitol.

A. Fasano, N. Eddington, N. N. Salama, 2003, International journal of pharmaceutics.

The role of P-glycoprotein in drug resistance in multiple myeloma

A. Azab, N. N. Salama, J. Abraham, 2015, Leukemia & lymphoma.

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.

K. Trinkaus, J. Grilley-Olson, B. V. Van Tine, 2019, The Lancet. Oncology.

Enhancing proteasome‐inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma

S. Achilefu, R. Vij, A. Azab, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.

S. Goddu, C. Tsien, N. Fettig, 2017, Journal of pharmaceutical sciences.

Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.

K. Trinkaus, B. Siegel, P. Oppelt, 2018, The Lancet. Oncology.

The Impact of ΔG on the Oral Bioavailability of Low Bioavailable Therapeutic Agents

A. Fasano, M. Thakar, N. Eddington, 2005, Journal of Pharmacology and Experimental Therapeutics.

The effect of ΔG on the transport and oral absorption of macromolecules

A. Fasano, M. Thakar, N. Eddington, 2004 .

Enhanced Permeability of Molecular Weight Markers and Poorly Bioavailable Compounds Across Caco-2 Cell Monolayers Using the Absorption Enhancer, Zonula Occludens Toxin

N. Eddington, D. Cox, N. N. Salama, 2002, Pharmaceutical Research.

The effect of delta G on the transport and oral absorption of macromolecules.

A. Fasano, M. Thakar, N. Eddington, 2004, Journal of pharmaceutical sciences.

Should Torsion Balance Technique Continue to be Taught to Pharmacy Students?

Rasma S. Chereson, N. N. Salama, R. Bilger, 2017, American Journal of Pharmaceutical Education.

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance

R. Vij, A. Azab, F. Azab, 2017, Leukemia & lymphoma.

Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma

S. Achilefu, R. Vij, A. Azab, 2016, Haematologica.

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

A. Azab, F. Azab, N. N. Salama, 2016, Blood Cancer Journal.

Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.

Michael Heung, Jonathan H. Segal, N. N. Salama, 2021, The Journal of antimicrobial chemotherapy.

The role of P-glycoprotein in drug resistance in multiple myeloma

A. Azab, N. N. Salama, J. Abraham, 2015, Leukemia & lymphoma.

Buparlisib (NVP-BKM-120)

A. Azab, F. Azab, N. N. Salama, 2013, Drugs of the Future.